A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Carotuximab (Primary) ; Everolimus; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions
- 27 Dec 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.
- 10 Jun 2017 Biomarkers information updated
- 11 May 2016 According to a company media release, TRACON anticipates top-line data from this trial in 2017.